— Reported sales increased 3.9%; organic sales increased 2.8% — Increases full year organic sales growth outlook to +2.0% to +3.0% — Increases full year earnings per share outlook to $5.80 to $5.95 Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2025. https://mma.prnewswire.com/media/2369614/Solventum_Logo.jpg Second Quarter 2025 Highlights — Sales […]
(NASDAQ:APYX), CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation, an advanced energy technology company and manufacturer of Renuvion(R) and the newly launched AYON Body Contouring System(TM), today announced the strategic appointments of two accomplished sales executives to its leadership team. These additions support the Company's continued global expansion and the commercial launch
(NASDAQ:SGHT), MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its
(NasdaqGM:ETNB), – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026 – – Cash, cash equivalents, and marketable
(NASDAQ:FDUS), Board of Directors Declared Total Dividends of $0.57 per Share for Third Quarter 2025 Base Dividend of $0.43 and Supplemental Dividend of $0.14 Per Share EVANSTON, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) — Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market
(NASDAQ:MDGL), CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2025 to 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The
(NASDAQ:PCT), ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today a corporate update for the second quarter ending June 30, 2025. Management Commentary PureCycle CEO Dustin Olson commented, “We have begun to implement our growth plans following our successful $300 million capital raise
(NASDAQ:VTYX), Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson's disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to
(NasdaqGM:RXST), ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing
(NASDAQ:RXT), Revenue of $666 million in the Second Quarter, down 3% Year-over-Year Private Cloud Revenue was $250 million, down 4% Year-over-Year Public Cloud Revenue was $417 million, down 2% Year-over-Year Second Quarter 2025 Cash Flow From Operating Activities was $8 million; Cash Flow From Operating Activities was $127 million on a Trailing-Twelve-Month Basis SAN ANTONIO,